Fact checked by Jim Lacy
Because many cancers have no known biomarkers — molecules found in the body that link to a specific condition — those cancers are often discovered in patients
at later stages. But that’s starting to change.
Exact Sciences, in Madison, Wisconsin, has identified biomarkers that predict very early-stage cancer, before people experience symptoms. In August 2024, the company announced the Multi-Cancer Early Detection (MCED) study, to test its findings.
Endeavor Health is one of two health systems nationwide currently participating in the study; the system will enroll up to 5,000 people between 50 and 80 years of age, with no history of cancer. Participants will undergo three blood draws over three years, and are followed for two years beyond that.
Researchers examine the blood closely, “looking for markers in blood to show you have cancer,” says Mark Dunnenberger, PharmD, who is running the study for Endeavor. If any of the blood draws indicate an early-stage cancer, the person is referred to the appropriate specialists for further testing.
“We are so excited,” Dunnenberger says. “It could be revolutionary in cancer screening if it works well. And so far, it’s working well.”
Originally published in the Spring/Summer 2025 print issue.
Ronit Rose is a freelance writer, based in Chicago. She has a special interest in health, healthcare and preventive medicine.
